News
Eli Lilly vs. Johnson & Johnson: Dividend King vs. Growth Juggernaut
A new analysis pits Eli Lilly’s explosive GLP-1 growth against Johnson & Johnson’s 60-year dividend streak, highlighting two starkly different investment styles in healthcare.
Qiang Sheng